Design Therapeutics (DSGN) logo

Design Therapeutics (DSGN) stock

Inherited disease therapeutics , market cap $597M

$9.02
-3.22%

Why is DSGN down?

Down 9% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.

  • Its Nov 4 results: net loss per share, basic and diluted widened to $0.32, from $0.30 a year before. It fell 9% on Nov 5.

Sources: Price history, Nov 5, 2026; Company release, Nov 4, 2026

−1Long-term trend below a falling 200-day average

Tell me next time DSGN moves

Free account, no card. An optional alert when DSGN moves or its score changes.Pro, $1 for a first month. An optional alert when DSGN moves or its score changes.Pro, 7 days free with a card. An optional alert when DSGN moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on DSGN →2 more reasons why DSGN fell on Nov 5, from its filings, with how the business stands, the timeline, and its peers, for Pro members.

Why DSGN still beats the market over three years

Up 305% over the three years to Nov 20 while the S&P 500 rose 58%; down 9% on Nov 5.

The reasons, from its filings, with the timeline, for Pro members.

Quality Score
-5
Poor
In its industry
#180of 273
Checks firing
0of 14
Transition
From 52-week high
-47.7%
under its best in a year

DSGN's Quality Score was unchanged on Fri, Nov 20, at -5.

Follow DSGN's trial news. Pro members can get an alert when Design Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when DSGN files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ1 2027“…the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027…”Trial data · SEC filing · Nov 4

Key facts on DSGN

Key facts on DSGN
Holding it backA $74M loss wider than $67M a year earlier
Its scoreDown:Lowest Quality Score since Jun 2025 Scores before Sep 10, 2026 were rebuilt.
Latest filing8-K, Nov 4 Reported its quarterly results

DSGN in the news

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

DSGN catalysts

Coming up

After its last 4 reports it closed +3.8% on average, higher 2 of 4 times.

What's next for DSGN, and how long its cash lasts

Next step the company has named

Q1 2027“Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027.”Trial data · SEC filing · Nov 4

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's AtaxiaPhase 1/2 · Recruiting · 20 people · main data estimated Dec 2026 · NCT06874010

2 more trials, 1 more milestone and 20 filings, for Pro members.

Cash runway

The company says its cash lasts into 2029 (8-K, Apr 28).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Nov 4, 2026)
  • At-the-market share sales program (S-3, filed Nov 4, 2026)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Pratik Shah’s 8 filings and quotes.

Get an alert when DSGN files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How DSGN ranks in Biotech

DSGN is #180 of 273 by Quality Score.

How DSGN ranks in Biotech
RankStockQuality Score
180Design Therapeutics (DSGN) logoDSGNDesign Therapeutics-5

More in Biotech

When does DSGN report earnings, and what happens after?

Expected to report Tue Mar 9, after the close (in 108 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What DSGN reported on Nov 4, 2026

The quarter

A loss of $0.32 a share, from $0.30.

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

DSGN's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value
$597M
today
Sales
$0
last 12 months
Free cash flow
-$59.4M
last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on DSGN: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+23.3%+4.8%-9.0%
Apr 28Aug 3Nov 4
ReportedGapReaction5
days
Nov 4, 2026After close+1.1%-9.0%+1.3%
Aug 3, 2026Before open-1.1%+4.8%+14.9%
Apr 28, 2026After close+1.5%+23.3%+4.7%

DSGN closed higher after 2 of its last 4 reports.

All 4 reports, and DSGN's Quality Score going into each

DSGN sales and profit by year

Profit by year

Sales fell in 2025, to $0. It lost money in both years.

Nothing is firing on DSGN right now

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on DSGN, and all 14 on every stock.Get in free →See the top 3 →Start Pro

DSGN RSI on Nov 20: 32.8, below its 50-day and 200-day averages

Not scored

RSI 32.8, MACD below signal, below both averages. Not scored.

DSGN share count over time

Shares: 10.7% more than a year ago (to Sep 30).

Shares of DSGN outstanding, as filed
Shares
outstanding
As
of
64MOct 30, 2026
62.6MJul 29, 2026
62.5MApr 23, 2026
61.7MMar 2, 2026
Offerings, shelves, and splits of DSGN, from its filings
From its
filings
Filed
Set up an at-the-market program for up to $200M of shares, about 34% of its market valueNov 4, 2026
Registered shares for a later sale (S-3)Nov 4, 2026
Registered shares for a later sale (S-3)May 7, 2025

Which ETFs hold DSGN?

In ETFs: DSGN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Design Therapeutics

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

60 employeesCarlsbad, CAdesigntx.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on DSGN and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn DSGN's score around: 8 things
  • 5 more filings explained, a plain line each
  • 4 more things pulling DSGN's score down

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: DSGN's Quality Score is -5 (Poor), #180 of 273 in Biotech.

What does DSGN's Quality Score say?

DSGN scores -5 today, which Breakaway calls Poor. It is #180 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 9% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%. Shares: 10.7% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is DSGN's Quality Score?

DSGN scores -5 today, which Breakaway calls Poor (below zero). That is #180 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DSGN's -5.

When does DSGN report earnings?

Expected to report Tue Mar 9, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. DSGN closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Design Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.